Cardiol Therapeutics A

At the H.C. Wainwright conference, Cardiol Therapeutics announced that recruitment for the approval-relevant Phase-III study MAVERIC in recurrent pericarditis is close to the 110-patient target and that top-line data after database lock are expected in the first quarter. Phase-II data from ARCHER support the likelihood of success; the program has FDA orphan status and the study design was aligned with regulators. In parallel, the company is advancing the preclinical CRD-38 program for a monthly subcutaneous cardiac therapy and plans a first-in-human application within the next 12 months; management sees commercial opportunities for an orally available, more attractively priced CardiolRx. » Więcej na de.investing.com

Cardiol Therapeutics has filed a preliminary short-form shelf prospectus with Canadian regulators and a Form F-10 with the U.S. SEC, which could allow the company to offer up to US$150 million of shares, debt securities and other instruments over 25 months. No securities are currently being offered and the filing does not obligate an offering. At the request of the Ontario Securities Commission, Cardiol supplemented MD&A disclosures for the year ended 31.12.2025 and for periods up to 30.06.2026, including schedules and costs for R&D, a breakdown of G&A expenses and details on the use of proceeds from the October 2024 financing; previously released financial statements were not amended. Material contracts with Dalton Chemical Laboratories, Purisys and a CRO of the Instituto Tecnológico y de Estudios Superiores de Monterrey were also filed. Cardiol is developing anti-inflammatory and antifibrotic therapies; the Phase III MAVERIC study is testing CardiolRx in recurrent pericarditis. » Więcej na de.investing.com

Cardiol Therapeutics announced at the Canaccord Growth Conference that MAVERIC phase‑III data on prevention of recurrences after stopping rilonacept should be available in roughly seven months. The 110‑patient study aims for a 40% relative risk reduction; earlier phase‑II data showed a strong signal with 71% of patients remaining recurrence‑free on CardiolRx monotherapy. Management sees large market potential (IL‑1 blocker market >1 billion CAD), expects possible pricing levels of up to 60% of rilonacept, and is preparing a regulatory filing if results are positive; programs for myocarditis and heart failure (CRD‑38) are also underway. » Więcej na de.investing.com